Biomarker-Based SLE Dosing via Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating systemic lupus erythematosus (SLE) face challenges in predicting clinical sensitivity and therapeutic response to compounds, as the clinical efficacy of these compounds can only be measured after several months of treatment, making it difficult to develop efficient and accurate methods for detecting and characterizing pharmacodynamic activity.
Innovation Solution
The method involves obtaining a sample from a subject with SLE, measuring the gene expression level of IKZF3 or the gene expression levels of IFI27, IFI44, IFI44L, and RSAD2, and determining the dose of a treatment compound based on the calculated score relative to a reference level, where the treatment compound is a compound of Formula I or its pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, tautomers, or racemic mixtures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional clinical efficacy measurement methods are used, then treatment response can be accurately assessed, but the measurement process requires several months of treatment time
Solution Approach 1:
The patent applies preliminary action by measuring gene expression levels (IKZF3, IFI27, IFI44, IFI44L, RSAD2) before and during treatment to predict clinical response in advance. This allows the system to assess treatment efficacy through biomarker changes rather than waiting for clinical outcomes, effectively performing the assessment action beforehand based on molecular indicators.
Solution Approach 2:
The patent uses gene expression levels as an intermediary mediator between treatment administration and clinical efficacy assessment. Instead of directly measuring clinical outcomes which takes months, the system measures intermediate biomarker changes that correlate with treatment response, providing a faster proxy measurement that maintains predictive accuracy.
2Stability of the object's composition
If standardized treatment protocols are used, then treatment consistency is maintained, but individual patient response variability cannot be addressed
Solution Approach 1:
The patent applies local quality by tailoring treatment dosage and duration to each patient's specific biomarker profile. Instead of uniform treatment for all patients, the system measures individual gene expression levels and adjusts treatment parameters locally for each patient based on their predicted response, allowing standardized protocols to be customized at the individual level.
Solution Approach 2:
The patent implements dynamics by making treatment protocols adaptable and changeable based on measured biomarker responses. The treatment plan is not fixed but dynamically adjusted according to individual patient gene expression profiles and their changes during treatment, allowing the system to transition from static standardized protocols to flexible personalized regimens.
Data Source
AI summary
A method of determining a dose of a treatment compound for treating a subject having systemic lupus erythematosus (SLE), comprising obtaining a sample from the subject and measuring the gene expression level of IKZF3 and/or the gene expression levels of IFI27, IFI44, IFI44L, and RSAD2 in the sample.